Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included newly diagnosed women with HER2-positive invasive breast...

Full description

Bibliographic Details
Main Authors: Armstrong, A. (Author), Bliss, J.M (Author), Brunt, A.M (Author), Bundred, N. (Author), Cameron, D.A (Author), Cramer, A. (Author), Cutress, R.I (Author), Dodwell, D. (Author), Emson, M.A (Author), Evans, A. (Author), Hanby, A. (Author), Hartup, S.M (Author), Horgan, K. (Author), McIntosh, S.A (Author), Miller, S.E (Author), Morden, J.P (Author), Naik, J. (Author), Narayanan, S. (Author), Ooi, J. (Author), Porta, N. (Author), Rakha, E.A (Author), Shaaban, A.M (Author), Skene, A.I (Author)
Format: Article
Language:English
Published: American Association for Cancer Research Inc. 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items